RBC Capital analyst Randall Stanicky lowered his price target on Jazz Pharmaceuticals to $184 after its Q3 results, saying the company again “missed the mark” on Vyxeos whose launch continues to disappoint. The analyst keeps his Outperform rating on Jazz Pharmaceuticals, citing the “robust” 9% volume growth for Xyrem and its anticipated near-term launches, but believes that unlocking value for investors may take “longer than anticipated”.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.